Comparison of efficacy and tolerability of adjuvant therapy for resected high-risk stage III-IV cutaneous melanoma: a systemic review and Bayesian network meta-analysis
Background: Although immune checkpoint inhibitors (ICIs) and targeted therapies have been widely used as adjuvant treatment for resected melanoma, the optimal therapy remains controversial. Therefore, we conducted this updated network meta-analysis (NMA) to assess the efficacy and tolerability of ad...
Main Authors: | He Ba, Fangyuan Zhu, Xiaoze Zhang, Zubing Mei, Yaodong Zhu |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2023-01-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/17588359221148918 |
Similar Items
-
The Role of Adjuvant Radiotherapy for the Treatment of Resected High-Risk Stage III Cutaneous Melanoma in the Era of Modern Systemic Therapies
by: Seth Kibel, et al.
Published: (2023-12-01) -
The Proportion Cured of Patients with Resected Stage II–III Cutaneous Melanoma in Sweden
by: Hanna Eriksson, et al.
Published: (2021-05-01) -
Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial
by: Weber, J, et al.
Published: (2019) -
The cost of unresectable stage III or stage IV melanoma in Italy
by: Maio Michele, et al.
Published: (2012-11-01) -
Assessing the use of anti-PD1 monotherapy as adjuvant therapy and determinants of treatment choice in stage III cutaneous melanoma in the US
by: Eric D. Whitman, et al.
Published: (2024-03-01)